Newish Biotech (wuxi) Co., Ltd.
Clinical trials sponsored by Newish Biotech (wuxi) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental biologic aims to eliminate persistent HPV16 infection Results expected Nov 2026 (estimated)
- Experimental shot aims to clear stubborn HPV infection in the anal region Results expected Dec 2026 (estimated)
- New shot aims to reverse HPV-linked cervical damage Results expected May 2027 (estimated)
- Experimental shot aims to reverse HPV-Linked cervical precancer Results expected Jun 2027 (estimated)
- New shot aims to clear stubborn HPV infection in women Results expected Sep 2027 (estimated)
-
Experimental shot aims to reverse HPV-Linked cervical precancer
Disease control Not yet recruitingThis study tests an experimental biologic, NWRD09, in women aged 18 to 65 with HPV16-positive cervical high-grade squamous intraepithelial lesions (HSIL), a precancerous condition. Participants receive four intramuscular injections over 12 weeks. The main goal is to see if the tr…
Phase 2 • Sponsor: Newish Biotech (Wuxi) Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New shot aims to clear stubborn HPV infection in women
Disease control Not yet recruitingThis early-stage study tests a new drug called NWRD09 in 78 women aged 18-60 who have had a persistent HPV16 infection for at least 6 months. The goal is to see if the injection is safe and can help the body clear the virus. Participants will receive either the drug or a placebo,…
Phase 1/2 • Sponsor: Newish Biotech (Wuxi) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC